 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- || hydroxychloroquine inhalation (HCQ01) / Sana Pharma
PK/PD data, Journal: Safety, Tolerability, and Pharmacokinetics of Nebulized Hydroxychloroquine: A Pilot Study in Healthy Volunteers. (Pubmed Central) - Apr 17, 2023
The reported systemic exposure was very low with a mean value of 5.28 (0.6-15.6) ng
- | hydroxychloroquine inhalation (HCQ01) / Sana Pharma
Enrollment change, Trial withdrawal: The Potential Use of Inhaled Hydroxychloroquine for the Treatment of COVID-19 in Cancer Patients (clinicaltrials.gov) - Apr 7, 2023
P1/2, N=0, Withdrawn, Sponsor: King Hussein Cancer Center
The reported systemic exposure was very low with a mean value of 5.28 (0.6-15.6) ng N=28 --> 0 | Not yet recruiting --> Withdrawn
- | hydroxychloroquine inhalation (HCQ01) / Sana Pharma
Trial completion date, Trial primary completion date: The Potential Use of Inhaled Hydroxychloroquine for the Treatment of COVID-19 in Cancer Patients (clinicaltrials.gov) - Jun 30, 2022
P1/2, N=28, Not yet recruiting, Sponsor: King Hussein Cancer Center
N=28 --> 0 | Not yet recruiting --> Withdrawn Trial completion date: Jan 2022 --> Dec 2022 | Trial primary completion date: Jan 2022 --> Nov 2022
- | hydroxychloroquine inhalation (HCQ01) / Sana Pharma
Enrollment open, Trial initiation date: The Potential Use of Nebulized Hydroxychloroquine for the Treatment of COVID-19 (clinicaltrials.gov) - Mar 7, 2022
P2, N=110, Recruiting, Sponsor: Ministry of Health Jordan
Trial completion date: Jan 2022 --> Dec 2022 | Trial primary completion date: Jan 2022 --> Nov 2022 Not yet recruiting --> Recruiting | Initiation date: Dec 2021 --> Mar 2022
- | hydroxychloroquine inhalation (HCQ01) / Sana Pharma
New P2 trial: The Potential Use of Nebulized Hydroxychloroquine for the Treatment of COVID-19 (clinicaltrials.gov) - Nov 8, 2021
P2, N=110, Not yet recruiting, Sponsor: Ministry of Health Jordan
- | hydroxychloroquine inhalation (HCQ01) / Sana Pharma
Trial completion date, Trial initiation date, Trial primary completion date: The Potential Use of Inhaled Hydroxychloroquine for the Treatment of COVID-19 in Cancer Patients (clinicaltrials.gov) - Jul 1, 2021
P1/2, N=28, Not yet recruiting, Sponsor: King Hussein Cancer Center
Not yet recruiting --> Recruiting | Initiation date: Dec 2021 --> Mar 2022 Trial completion date: Sep 2021 --> Jan 2022 | Initiation date: Mar 2021 --> Jul 2021 | Trial primary completion date: Sep 2021 --> Jan 2022
- | hydroxychloroquine inhalation (HCQ01) / Sana Pharma
New P1/2 trial: The Potential Use of Inhaled Hydroxychloroquine for the Treatment of COVID-19 in Cancer Patients (clinicaltrials.gov) - Jan 28, 2021
P1/2, N=28, Not yet recruiting, Sponsor: King Hussein Cancer Center